Clinical trial NCT00816712: A Study to Evaluate the Effect of Testosterone on Muscle Fractional Synthetic Rate (MK-0000-064)
Official title: A Randomized, Single-Blind, Placebo-Controlled, Single-dose, Parallel Design Study to Evaluate the Effect of Testosterone on Muscle Fractional Synthetic Rate (FSR)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Muscle Anabolism
Keywords: Males with low-normal serum total testosterone levels.
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2009-01-05
Enrollment: 28
Sex: MALE
Minimum age (years): 60
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a study to evaluate the use of fractional synthetic rate as an early biomarker of muscle anabolism (muscle build-up).


Eligibility criteria: Inclusion Criteria:

* Subject is weight stable over the past 3 months
* Patient agrees to refrain from consumption of alcohol from 48 hours prior to entering the study
* Subject agrees to follow the study restriction of no caffeine while on study
* Patient agrees to following the meat-free controlled protein weight-maintaining diet
* Patient is willing to avoid strenuous physical activity
* Patient has been a nonsmoker for at least 6 months prior to study start

Exclusion Criteria:

* Subject is currently a regular user of any illicit drugs
* Subject has taken androgenic steroids in the previous 12 months
* Subject has participated in sports events, resistance exercise training or heavy exercise in the previous month
* Subject has prostate cancer
* Subject has a history of cancer except basal-cell tumors
* Subject has been diagnosed with HIV
* Subject has been diagnosed with Hepatitis B or C
* Subject uses certain anti-inflammatory drugs such as ibuprofen, arcoxia or celecoxib
* Subject uses a blood anticoagulant, such as Coumadin (Warfarin) or high doses of aspirin
* Subject is currently taking over the counter supplements such as "muscle builders" or "fat burners"
* Subject has an allergy or hypersensitivity to intramuscular testosterone
* Subject has sciatica
* Subject has donated blood products or has had phlebotomy within 2 months of signing informed consent
* Subject has undergone a surgical procedure within 1 month of signing informed consent
* Subject is currently participating or has participated in a study with an investigational drug or device

Primary outcomes:
measure: Thigh (vastus lateralis) muscle protein fractional synthetic rate one week after dosing with testosterone.
timeFrame: One week
Secondary outcomes:
measure: Variability in the muscle fractional synthetic rate measurements.
timeFrame: One week
Other outcomes:
Locations:
Study officials:
affiliation: Merck Sharp & Dohme LLC
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Chen F, Lam R, Shaywitz D, Hendrickson RC, Opiteck GJ, Wishengrad D, Liaw A, Song Q, Stewart AJ, Cummings CE, Beals C, Yarasheski KE, Reicin A, Ruddy M, Hu X, Yates NA, Menetski J, Herman GA. Evaluation of early biomarkers of muscle anabolic response to testosterone. J Cachexia Sarcopenia Muscle. 2011 Mar;2(1):45-56. doi: 10.1007/s13539-011-0021-y. Epub 2011 Feb 26.